Spain claims EU biomedical R&D (research and development) directive first:
This article was originally published in Clinica
Spain is claiming to be the first country in the EU to meet the directive on biomedical research, which sets out programmes for EU-wide collaborations. Spain has allocated E540m ($531m) in 2002-05 to a programme of initiatives aimed at improving healthcare research. These include improving collaboration across the different areas of the national R&D programme and to more directly involve the national health system, ahead of its integration into the future EU-wide research network. The Instituto de Salud Carlos III will be responsible for managing the programme. The ministries of health and of science admit that 42% of Spanish research is not co-ordinated.
You may also be interested in...
Sandoz announced more than a year ago that its GP2411 biosimilar denosumab candidate had entered the clinic. Management provided an update on its progress at the recent Virtual Meet Novartis Management Investor Event.
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from fellow Indian firm Glenmark.
Sandoz has launched an awareness campaign under the banner of “Ask For Generics” in the US. The initiative is aiming to educate stakeholders on the benefits of generics and their quality, safety and efficacy.